SEARCH:   Advanced

Blood, 15 October 2008, Vol. 112, No. 8, pp. 3500-3507. Prepublished online as a Blood First Edition Paper on July 29, 2008; DOI 10.1182/blood-2008-02-141689. This Article Full Text (PDF) Supplemental Tables All Versions of this Article: blood-2008-02-141689v1 112/8/3500    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lee, S. J Articles by Maziarz, R. T Search for Related Content PubMed PubMed Citation Articles by Lee, S. J Articles by Maziarz, R. T Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 25, 2008 Accepted June 30, 2008 Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia Stephanie J Lee*, Manisha Kukreja, Tao Wang, Sergio A Giralt, Jeffrey Szer, Mukta Arora, Ann E Woolfrey, Francisco Cervantes, Richard E Champlin, Robert Peter Gale, Joerg Halter, Armand Keating, David I Marks, Philip L McCarthy, Eduardo Olavarria, Edward A Stadtmauer, Manuel Abecasis, Vikas Gupta, H. Jean Khoury, Biju George, Gregory A Hale, Jane L Liesveld, David A Rizzieri, Joseph H Antin, Brian J Bolwell, Matthew H Carabasi, Edward Copelan, Osman Ilhan, Mark R Litzow, Harry C Schouten, Axel R Zander, Mary M Horowitz, and Richard T Maziarz Fred Hutchinson Cancer Research Center, Seattle, WA, United States Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, United States M.D. Anderson Cancer Center, Houston, TX, United States Royal Melbourne Hospital, Parkville, Australia University of Minnesota Medical Center, Minneapolis, MN, United States Hospital Clinic, Barcelona, Spain Center for Advanced Studies in Leukemia, Los Angeles, CA, United States University Hospital Basel, Basel, Switzerland Princess Margaret Hospital for Children, Toronto, Ontario, Canada Bristol Children's Hospital, Bristol, United Kingdom Roswell Park Cancer Institute, Buffalo, NY, United States Hammersmith Hospital, London, United Kingdom Hospital of the University of Pennsylvania, Philadelphia, PA, United States Instituto Portugues de Oncologia, Lisboa, Portugal Emory University School of Medicine, Atlanta, GA, United States Christian Medical College Hospital, Tamil Nadu, India St. Jude Children's Research Hospital, Memphis, TN, United States University of Rochester Medical Center, Rochester, NY, United States Duke University Medical Center, Durham, NC, United States Dana-Farber Cancer Institute, Boston, MA, United States Cleveland Clinic Foundation, Cleveland, OH, United States Thomas Jefferson University Hospital, Philadelphia, PA, United States Ibni Sinai Hospital, Ankara, Turkey Mayo Clinic Rochester, Rochester, MN, United States University Hospital Maastricht, Maastricht, Netherlands University Hospital Eppendorf, Hamburg, Germany Oregon Health & Science University, Portland, OR, United States * Corresponding author; email: sjlee{at}fhcrc.org. Imatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT raising the question of whether prior IM therapy impacts HCT success. Data from the Center for International Blood and Marrow Transplant Research on 409 subjects treated with IM before HCT (IM+) and 900 subjects who did not receive IM prior to HCT (IM-) were analyzed. Among patients in first chronic phase, IM therapy prior to HCT was associated with better survival but no statistically significant differences in treatment-related mortality (TRM), relapse and leukemia-free survival (LFS). Better HLA matched donors, use of bone marrow, and transplantation within one year of diagnosis were also associated with better survival. A matched-pairs analysis was performed and confirmed a higher survival rate among first chronic phase patients receiving IM. Among patients transplanted with advanced CML, use of IM before HCT was not associated with TRM, relapse, LFS or survival. Acute graft-versus-host disease rates were similar between IM+ and IM- groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. Jabbour, J. E. Cortes, and H. M. Kantarjian Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Mayo Clin. Proc., February 1, 2009; 84(2): 161 - 169. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020